MBMira Beisembayeva

Mira Beisembayeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mira Beisembayeva has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbidity Burden and Early In‐Hospital Outcomes After Intravenous Thrombolysis for Acute Ischemic Stroke

    by Sharbanu Battakova, Marina Grigolashvili, Dmitry Kasatkin, Irina Kadyrova, Yelena Shayakhmetova, Mira Beisembayeva, Shynar Muratbekova, Ivan Turkevich, Alina Koshelyuk

    Background: The prognostic relevance of comorbidity burden in patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT) remains uncertain. This study examined the association between four comorbidity indices and early in‐hospital outcomes. Methods: This single‐center retrospective study included 106 patients with AIS treated with IVT between January and December 2024. Comorbidity burden was assessed using the Charlson Comorbidity Index (CCI; 1987 and 2011 versions) and the Elixhauser Comorbidity Index (ECI; 2009 and 2017 versions). The primary outcome was unfavorable functional status at discharge, defined as a modified Rankin scale (mRS) score of 3–6. Multivariable logistic regression was used to identify factors associated with the primary outcome, and receiver operating characteristic (ROC) analyses assessed the discriminatory performance of the indices. Mortality comparisons were exploratory because only 10 in‐hospital deaths occurred. Results: The median age was 68 years, and 60 patients (56.6%) were men. Unfavorable functional outcome (mRS 3–6) occurred in 73 patients (68.9%). Higher admission National Institutes of Health Stroke Scale (NIHSS) scores and glucose levels were independently associated with unfavorable functional status at discharge, whereas none of the four comorbidity indices remained significant after multivariable adjustment. The comorbidity indices showed limited to modest discriminatory performance, with an AUC of 0.645 (95% CI 0.531–0.760) for CCI 1987. Hemorrhagic transformation (HT) occurred exclusively in patients with an unfavorable outcome and was more frequent among nonsurvivors. Exploratory comparisons also showed higher prestroke mRS, admission NIHSS, CCI 1987, and CCI 2011 scores among nonsurvivors; no multivariable mortality analysis was performed. Conclusions: None of the evaluated comorbidity indices was independently associated with functional status at hospital discharge. Their discriminatory performance was modest, whereas admission stroke severity and glucose level showed stronger associations with short‐term outcome. Given the retrospective single‐center design, modest sample size, and limited number of deaths, the findings should be considered exploratory and hypothesis‐generating and require confirmation in larger prospective studies.

  • Open Access

    A Comparative Analysis of the Gut Microbiota in Patients With Parkinson’s Disease Worldwide: A Systematic Review

    by Mira Beisembayeva, Yelena Shayakhmetova, Shynar Muratbekova, Irina Li, Eduard Yakupov, Rauan Kaiyrzhanov, Marina Grigolashvili

    Background: Parkinson’s disease (PD) is a neurodegenerative disease associated with the gut microbiome. Objective: Conducting a comparative analysis of the intestinal microbiome in PD patients from different geographical regions. Methods: Two researchers conducted a systematic literature review of the Web of Science, PubMed, and Scopus databases, using specific search terms and defined inclusion and exclusion criteria to select studies. This is the first systematic review that conducted an analysis of the gut microbiota of PD patients from all continents. Results: The α‐diversity of PD patients does not differ significantly from healthy individuals in Europe and America, in contrast to Asia and Australia. β‐Diversity varies among PD patients in different continents. In all regions, there has been an increase in Proteobacteria and Lactobacillaceae and a decrease in Lachnospiraceae and Roseburia . In Europe, Asia, and America, PD patients have shown an increase in Bifidobacteriaceae, Desulfovibrio , Verrucomicrobia, Bilophila , and Akkermansia and a decrease in Lachnospira . In Asia, America, and Australia, there has been a decrease in Fusicatenibacter and Lachnospiraceae ND3007 , while in Europe, America, and Australia, there has been a reduction in Butyricicoccus . Conclusions : There were no consistent patterns in the changes in α‐ and β‐diversities of the gut microbiota among PD worldwide. Across all continents, there was an increase in Proteobacteria and Lactobacillaceae and a decrease in Lachnospiraceae and Roseburia . Despite these similar trends, there were also differences that may be attributed to factors such as ethnic background, geography, and dietary habits. These differences suggest that individualized approaches to treatment may be necessary to effectively manage PD‐related gastrointestinal symptoms.


  • Анализ заболеваемости верифицированных случаев миастении в центральном Казахстане

    by М.а. Григолашвили, Н.а. Евстафьева, Ш.с. Муратбекова, М.б. Бейсембаева, А.а. Серёгина, Ю.а. Приходченко, Д.х. Насырова